In this exploratory study, we investigated the response of a panel of twenty well-characterized human CRC organoid lines derived from colon cancers [18] to treatment with the EZH2 inhibitor GSK126 over a course of multiple weeks. This evidence concerns the gene EZH2 and colonic neoplasm.